Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

SpyGlass Pharma, Inc. Common Stock

SGP

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

Last trade $31.19
Day change -$1.05 (-3.26%)
Day range $30.15 – $32.72
Volume 37,713
Market cap $1.08B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.08B
Price / earnings
—
Price / book
5.13×
Price / sales
—
EV / sales
—
EV / EBITDA
-11.81×

Profitability

Earnings per share
-$2.02
Return on assets
-29.93%
Return on equity
-32.19%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
15.24×
Quick ratio
15.24×
Cash ratio
14.6×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$58.47M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SGP, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026
Revenue$0$0$0
Cost of revenue$0$0$0
Gross profit$0$0$0
Selling, general and administrative$16.21M$11.03M$6.87M
Research and development$10.03M$10.94M$8.54M
Total operating expenses$26.25M$21.97M$15.41M
Operating income-$26.25M-$21.97M-$15.41M
Interest expense$0$0$0
Income before taxes-$24.25M-$19.86M-$13.82M
Income taxes$0$0$0
Net income-$24.25M-$19.86M-$13.82M
Net income attributable to common shareholders-$24.25M-$19.86M-$13.82M
EBITDA-$25.97M-$21.63M-$15.09M
Basic earnings per share-$0.73-$0.59-$0.69
Diluted earnings per share-$0.73-$0.59-$0.69

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

SpyGlass Pharma Appoints Shannon Treviño as General Counsel

SpyGlass Pharma, a late-stage biopharmaceutical company, announced the appointment of Shannon Treviño as general counsel. Treviño brings extensive legal experience from her previous role as General Counsel at Inari Medical, where she oversaw the company's $4.9 billion acquisition by Stryker. She will support SpyGlass's Phase 3 trials for its BIM-IOL System, a drug delivery device designed to treat glaucoma and ocular hypertension.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Oct 22, 2009$0.065Nov 30, 2009recurring
Aug 5, 2009$0.065Aug 31, 2009recurring
Apr 29, 2009$0.065May 26, 2009recurring
Feb 4, 2009$0.065Feb 27, 2009recurring
Nov 5, 2008$0.065Nov 25, 2008unknown

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.